Related Experiment Video
Updated: Jul 13, 2026
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma
Cynthia Spittle1, M Renee Ward, Katherine L Nathanson
1Clinical Translational Medicine, Oncology, Wyeth Research, 500 Arcola Rd., Collegeville, PA 19426, USA.
Abstract:
Mutations in the BRAF gene are found in the majority of cutaneous malignant melanomas and subsets of other tumors. These mutations lead to constitutive activation of BRAF with increased downstream ERK (extracellular signal-regulated kinase) signaling; therefore, the development of RAF kinase inhibitors for targeted therapy is being actively pursued. A methodology that allows sensitive, cost-effective, high-throughput analysis of BRAF mutations will be needed to triage patients for specific molecular-based therapies. Pyrosequencing is a high-throughput, sequencing-by-synthesis method that is particularly useful for analysis of single nucleotide polymorphisms or hotspot mutations. Mutational analysis of BRAF is highly amenable to pyrosequencing because the majority of mutations in this gene localize to codons 600 and 601 and consist of single or dinucleotide substitutions. In this study, DNAs from a panel of melanocyte cell lines, melanoma cell lines, and melanoma tumors were used to validate a pyrosequencing assay to detect BRAF mutations. The assay demonstrates high accuracy and precision for detecting common and variant exon 15 BRAF mutations. Further, comparison of pyrosequencing data with 100K single nucleotide polymorphism microarray data allows characterization of BRAF amplification events that may accompany BRAF mutation. Pyro-sequencing serves as an excellent platform for BRAF genotyping of tumors from patients entering clinical trial.
Insights
Pyrosequencing accurately detects BRAF mutations, crucial for targeted melanoma therapies. This cost-effective method aids patient stratification for BRAF kinase inhibitor treatments.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- BRAF gene mutations drive melanoma and other cancers, leading to uncontrolled ERK signaling.
- Targeted therapies like RAF kinase inhibitors are under development, necessitating precise BRAF mutation detection.
- Efficient, high-throughput methods are essential for patient selection in molecular-based cancer treatments.
Purpose of the Study:
- To validate a pyrosequencing assay for sensitive and cost-effective detection of BRAF mutations.
- To assess the assay's accuracy and precision in identifying common and variant BRAF mutations in exon 15.
- To explore the utility of pyrosequencing for BRAF genotyping in clinical trial settings.
Main Methods:
- Utilized DNA from melanocyte and melanoma cell lines, as well as melanoma tumors.
- Applied pyrosequencing, a sequencing-by-synthesis method, for BRAF mutational analysis.
- Compared pyrosequencing data with 100K single nucleotide polymorphism microarray data.
Main Results:
- The pyrosequencing assay demonstrated high accuracy and precision for detecting BRAF mutations in exon 15.
- The method effectively identified both common and variant BRAF mutations.
- Integrated analysis with microarray data allowed for the characterization of BRAF amplification events.
Conclusions:
- Pyrosequencing is a suitable platform for BRAF genotyping.
- The validated assay can accurately detect BRAF mutations in melanoma and other tumors.
- This method supports patient stratification for targeted BRAF-directed therapies in clinical trials.
